What Researchers Did
Researchers conducted a literature review to evaluate the use of hyperbaric oxygen therapy (HBO₂) for osteonecrosis of the femoral head (ONFH).
What They Found
The review identified eight clinical studies, including two randomized controlled trials, one historically controlled study, and five case series. In studies where HBO₂ therapy was used alone, hip survivorship was reported as 95.5% for Steinberg Stage I lesions, 89% for Steinberg Stage II lesions, and 100% for Ficat Stage II lesions.
What This Means for Canadian Patients
Canadian patients with osteonecrosis of the femoral head may consider discussing hyperbaric oxygen therapy as a potential treatment option with their healthcare providers. However, current evidence suggests it may be more effective for early-stage lesions, and further robust research is needed to confirm its specific benefits.
Canadian Relevance
This study has no direct Canadian connection as it was not conducted in Canada, nor does it involve Canadian researchers or patients.
Study Limitations
The review was limited by the small scale, heterogeneity, and methodological weaknesses of the included studies, often combining HBO₂ therapy with other treatments.